Board of Directors

THPX05_About_72dpi_1575x325_170517-blue

About

Dr. Ascher Shmulewitz 

Has served as our Chairman since January 2014 and on our Board of Directors since February 2013 and was appointed our interim Chief Executive Officer since November 1, 2017 until May 6, 2020. Dr. Shmulewitz is an inventor, investor and serial entre­pre­neur in biomed­ical technolo­gies. Dr. Shmulewitz has founded and invested in over two dozen life science compa­nies including NeoVision Corp, Labcoat Medical Ltd., Arteria Corp., Circulation Inc. and X‑Cardia Inc., and has led multiple of these compa­nies to successful exits, including through merger and acqui­si­tion trans­ac­tions with large medical device compa­nies. Dr. Shmulewitz has vast experi­ence in the venture capital arena as an investor, manager and entre­pre­neur in dozens of compa­nies and ventures. In 1995, Dr. Shmulewitz co-founded San Francisco Science and the Incumed Group, compa­nies that provide seed funding, and is the founder of Medgenesis Partners Ltd., an Israeli private invest­ment firm and incubator that has invested in over a dozen ventures. Dr. Shmulewitz previ­ously held senior execu­tive positions at Advanced Technology Laboratories Inc. (from 1988 to 1992). Dr. Shmulewitz received an M.D. degree from The Technion Medical School and a Ph.D. degree in Engineering from Tel Aviv University, Israel.

 

Mr. Stephen M. Simes

Has served on our Board of Directors since December 2016. Mr. Simes currently serves as an advisor and consul­tant to biopharma compa­nies. Mr. Simes is a member of the Ops Team of SmartHealth Activator. Mr. Simes serves on the advisory board for NeuroLucent a biotech company working on novel approaches for the treat­ment of Alzheimer’s disease, in addition to several other startup biopharma compa­nies in oncology and 3D bioprinting. From March 2014 until January 2016, Mr. Simes served as chief execu­tive officer and a member of the board of direc­tors of RestorGenex Corporation, a company with a focus on oncology (acquired through merger by Diffusion Pharmaceuticals, Inc.). Prior to such time, Mr. Simes served as Vice Chairman, President and chief execu­tive officer and a member of the board of direc­tors of BioSante Pharmaceuticals, Inc. from 1998 until June 2013 when BioSante merged with and renamed to ANI Pharmaceuticals, Inc. BioSante, whose common stock was listed on The Nasdaq Global Market, was a specialty pharma­ceu­tical company focused on devel­oping products for women’s and men’s health. From 1994 to 1997, Mr. Simes was presi­dent and chief execu­tive officer and a member of the board of direc­tors of Unimed Pharmaceuticals, Inc. (currently a wholly owned subsidiary of AbbVie, Inc.), a company with a product focus on infec­tious diseases, AIDS, endocrinology and oncology. From 1989 to 1993, Mr. Simes was chairman, presi­dent and chief execu­tive officer of Gynex Pharmaceuticals, Inc., a company which concen­trated on the AIDS, endocrinology, urology and growth disor­ders markets. In 1993, Gynex was acquired by Savient Pharmaceuticals Inc. (formerly Bio-Technology General Corp.), and from 1993 to 1994, Mr. Simes served as Senior Vice President and director of Savient Pharmaceuticals Inc. Mr. Simes’s career in the pharma­ceu­tical industry started with G.D. Searle & Co. (now a part of Pfizer Inc.). Mr. Simes has a B.Sc. degree in Chemistry at Brooklyn College of the City University of New York and an M.B.A. in Marketing and Finance from New York University.

Mr. Todd Violette

 has served on our Board of Directors since February 2020. Mr. Violette has served as the presi­dent, chief execu­tive officer and director of Tide Pool Ventures Corporation since November 2013. In addition, Mr. Violette has served as chief finan­cial officer, interim chief execu­tive officer and director for the East West Pharma Group since July 2019, and as the chief execu­tive officer and director for Appyea Inc. since February 2020. Mr. Violette has a B.A. from University of Maryland in Behavioral Sciences.